Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Creative Biolabs provides a comprehensive suite of engineered CAR cell products designed to support translational research, preclinical development, and next-generation cell therapy innovation. Our portfolio encompasses multiple immune cell types and customizable CAR designs, providing flexible, high-performance solutions tailored to diverse research needs.
CAR engineered immune cells are produced by introducing a synthetic antigen-recognition receptor into T cells or other immune cell subsets. Once modified, these cells acquire the ability to selectively recognize and eliminate target cells expressing the corresponding antigen. This approach has reshaped the landscape of immuno-oncology and continues to create new opportunities in cancer research, immune regulation, and cell engineering. Leveraging extensive experience in vector design, gene transfer, and immune cell manufacturing, we support customizable CAR engineering, from receptor design through cell expansion and functional assessment, to accelerate your discovery programs.
| CAR Cell Type | Description |
|---|---|
![]() CAR γδ T Cells |
Engineered γδ T cells generated using viral or non-viral gene delivery, combining innate-like recognition with CAR-directed specificity. |
![]() CAR CIK Cells |
Cytokine-induced killer cells modified with CAR constructs, offering hybrid T-cell and NK-like cytotoxic characteristics. |
![]() CAR-iT Cells |
T cells differentiated from induced pluripotent stem cells and equipped with customizable CAR designs; suitable for standardized, scalable off-the-shelf research models. |
![]() CAR-Treg Cells |
CAR-engineered regulatory T cells used for studies of immune tolerance, inflammation modulation, and microenvironment control. |
![]() CAR Jurkat Cells |
Jurkat reporter cells expressing CAR constructs for early-phase signaling studies, construct screening, and functional evaluation. |
![]() TSCM CAR-T Cells |
CAR-modified stem-cell–memory T cells with enhanced persistence and self-renewal, supporting long-term immune research applications. |
![]() CAR Animal Cells |
CAR-engineered immune cells from multiple species for mechanistic studies, in vivo modeling, and cross-species evaluation. |
![]() CAR-MA Cells |
Genetically modified macrophages expressing CARs, enabling exploration of antigen-specific phagocytosis and tumor microenvironment reprogramming. |
![]() CAR-NK 92 Cells |
NK-92 cells engineered with CAR constructs, providing a uniform, easy-to-expand NK cell platform ideal for cytotoxicity assays, target validation, and preclinical immunotherapy research. |
Each cell product undergoes rigorous quality evaluation, including:
These measures ensure reproducibility, reliability, and readiness for advanced research applications.
We provide flexible CAR customization options, including:
A streamlined ordering workflow supports rapid project initiation, while dedicated technical specialists assist throughout the entire development process.
Comprehensive Service Coverage: From receptor design to engineered cell generation and characterization.
Diverse Cell Platforms: T cell, γδ T, iPSC-derived T, Treg, macrophage, CIK, and species-specific models.
Strict Quality Control: Ensuring batch-to-batch consistency and dependable research outcomes.
Scalable Customization: Flexible design options to meet discovery, optimization, and translational research needs.
Please browse the target below to find the right CAR cell product for you.
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
Associated Antigen Target
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION









